Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Investigational New Drugs|April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumorsCarol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
Molecular Cancer Therapeutics|October 5, 2013
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutationsPrasanth Ganesan, Filip Janku, Aung Naing, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Clinical Genitourinary Cancer|August 4, 2014
MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitorsDenis L F Jardim, Débora de Melo Gagliato, Gerald Falchook, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesDavid S Hong, Said M Sebti, Robert A Newman, et al.
Pageof 8